Renaissance Capital logo

Alto Neuroscience Priced, NYSE: ANRO

Phase 2 biotech developing biomarker-focused therapies for depression and schizophrenia.

Industry: Health Care

Latest Trade: $3.75 0.00 (0.0%)

First Day Return: +29.4%

Return from IPO: -76.6%

Industry: Health Care

We are a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Through insights derived from our scalable and proprietary Precision Psychiatry Platform, or our Platform, which applies rigorous data science and robust analytics to data gathered by neurocognitive assessments, electroencephalography, and wearable devices, we aim to discover brain-based biomarkers to better identify which patients are more likely to respond to our novel product candidates. We build upon and leverage vast data sets of longitudinal clinical and biomarker data from thousands of patients across central nervous system, or CNS, disorders, which we believe serves as a foundation for applying our approach across numerous patient populations. Ultimately, if we are successful, we believe our approach can substantially improve upon the traditional, all-comer approach to CNS drug development. Our current pipeline consists of five clinical-stage assets initially targeting major depressive disorder, or MDD, and schizophrenia populations characterized by independent brain-based biomarkers. Each of our clinical-stage product candidates has been evaluated through at least initial Phase 1 clinical trials and observed to be well tolerated. Our most advanced programs, including our two product candidates being evaluated in ongoing late-stage (Phase 2b or later) trials, are supported by prospectively replicated evidence of clinical activity in biomarker-characterized populations.
more less
IPO Data
IPO File Date 01/12/2024
Offer Price $16.00
Price Range $14.00 - $16.00
Offer Shares (mm) 8.0
Deal Size ($mm) $129
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 02/01/2024
Offer Price $16.00
Price Range $14.00 - $16.00
Offer Shares (mm) 8.0
Deal Size ($mm) $129
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Jefferies
TD Cowen
more
Company Data
Headquarters Los Altos, CA, United States
Founded 2019
Employees at IPO 63
Website www.altoneuroscience.com

Alto Neuroscience (ANRO) Performance